Corticosteroids in infant chronic lung disease

Submitted: February 29, 2016
Accepted: February 29, 2016
Published: September 30, 2004
Abstract Views: 509
PDF: 367
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Chronic lung disease (CLD), defined as chronic oxygen dependency at 36 weeks postmenstrual age, is increasing and associated with chronic respiratory morbidity and high health care utilisation at follow up. Many strategies, tested in randomised trials, have failed to reduce CLD. In contrast, corticosteroids if given systemically within the first two weeks after birth reduce CLD and may also favourably influence survival. Unfortunately, systemically administered corticosteroids have many acute side-effects and adversely affect long term neurodevelopmental outcome. If given by inhalation, corticosteroids have fewer adverse effects, but are less efficacious. Further research is required to accurately identify infants at highest risk of developing CLD, the corticosteroid dosage associated with a positive risk: benefit ratio and preferably a safer and more effective alternative therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

May, C., and A. Greenough. 2004. “Corticosteroids in Infant Chronic Lung Disease”. Monaldi Archives for Chest Disease 61 (3). https://doi.org/10.4081/monaldi.2004.696.

Similar Articles

<< < 82 83 84 85 86 87 

You may also start an advanced similarity search for this article.